Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. Company
    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
Real-time Quote. Real-time Euronext Paris - 01/24 11:39:37 am
14.23 EUR   -9.13%
08:19aEU Medicines Watchdog to Issue Decision on Pfizer's COVID-19 Pill in January
MT
07:29aEU regulator set to rule on Pfizer COVID pill by end-Jan, ahead of Merck
RE
01/20Top Premarket Decliners
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Valneva SE
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and has leveraged its expertise and capabilities both to successfully commercialize two vaccines and rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, COVID-19 and the chikungunya virus.
Sales per Business
20192020Delta
Commercialized Vaccines129.67102.8%65.9459.8% -49.15%
Vaccine Candidates-10.52-8.3%31.6028.6%-
Technology Services7.045.6%12.7811.6% +81.57%
EUR in Million
Sales per region
20192020Delta
United States63.9950.7%68.3662% +6.82%
Austria7.806.2%10.269.3% +31.55%
Canada24.4019.3%8.978.1% -63.25%
Germany10.508.3%7.266.6% -30.82%
Other Markets4.873.9%4.313.9% -11.47%
Other Europe5.344.2%4.223.8% -20.97%
United Kingdom8.616.8%2.892.6% -66.48%
Nordics11.238.9%2.872.6% -74.44%
Switzerland-10.55-8.4%0.220.2%-
EUR in Million
Managers
Name Title Age Since
Thomas Lingelbach Co-President & Chief Executive Officer 57 -
Franck Charles Marie Grimaud Co-President & Chief Business Officer 55 -
Peter Buhler Chief Financial Officer & Director 51 2021
Michael Möhlen Vice President-Technical Development - -
Andreas Meinke VP-Preclinical & Translational Research - -
Juan Carlos Jaramillo, Dr. Chief Medical Officer - 2020
Perry Denis Celentano Chief Operating Officer - 2021
James R. Sulat Vice Chairman-Supervisory Board 70 2013
Anne-Marie Graffin Member-Supervisory Board 60 2013
Laetitia Bachelot-Fontaine Head-Investor Relations & Corporate Communications - -
Members of the board
Name Title Age Since
Frédéric Grimaud Chairman-Supervisory Board 56 2012
James R. Sulat Vice Chairman-Supervisory Board 70 2013
Anne-Marie Graffin Member-Supervisory Board 60 2013
Sharon E. Tetlow Member-Supervisory Board 61 2020
Johanna Willemina Pattenier, Dr. Member-Supervisory Board 61 2020
Peter Buhler Chief Financial Officer & Director 51 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 99,888,424 90,204,975 90.3% 125,808 0.1% 76.5%
Stock B 0 17,961,041 0 0.0% 124,322 0.7%
Shareholders
NameEquities%
Groupe Grimaud La Corbière SA 13,704,830 13.0%
Bpifrance Participations SA /PRIVATE EQUITY/ 9,265,478 8.82%
Polar Capital LLP 4,583,968 4.36%
MVM Partners LLP 2,628,141 2.50%
CDC Croissance SA 1,207,901 1.15%
BlackRock Fund Advisors 1,095,824 1.04%
SK Vermögensverwaltung GmbH 745,180 0.71%
LSP Advisory BV 696,715 0.66%
General American Investors Co., Inc. (Investment Management) 650,000 0.62%
Lupus alpha Asset Management AG 567,000 0.54%
Holdings
NameEquities%Valuation
VALNEVA SE (VLA) 124,322 0.12% 3,463,785 USD
Markets and indexes
- PEA / SRD eligible : YES / YES
- Compartiment B
- CAC Mid 60 / CAC All Shares, CAC All-Tradable, CAC Mid Small, CAC PME, EnterNext© PEA-PME 150, Next 150, Next Biotech, PEA, PEA-PME, SBF 120
Stock Exchange Codes
- Bloomberg Code :  VLS:FP
- Reuters Code :  VLS.PA
- Datastream Code :  
Company contact information
Valneva SE
6 Rue Alain Bombard
FR-44800 Saint-Herblain

Phone : +33 (0)2 28 07 37 10
Fax :
web site : http://www.valneva.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Valneva SE
Sector Other Biotechnology & Medical Research